Cell line development (CLD) plays a pivotal role in determining the robustness and cost-effectiveness of downstream bioprocessing development. Great Bay Bio developed a proprietary AlfaCell platform that applies Site-Specific Integration (SSI) technology and AI-enabled cell selection to accurately insert the target genes into specific “hot spot” within the genome of a host cell line. AlfaCell platform significantly reduces time, effort, and cost that are associated with the development of high-performance mammalian cell lines.
Only one 96-well plate for monoclone screening and only 3 months for monoclone.
Higher-than-industry-average titer and quality, 100% stability.
Obtain predictive cell pools within 6 weeks. Able to kick off ADC and BsAb process development and quality assessment ahead of schedule.